Evidence map›Paper›PMID 35324969›Full record

ArticlePloS one2022

A Factor H-Fc fusion protein increases complement-mediated opsonophagocytosis and killing of community associated methicillin-resistant Staphylococcus aureus.

Megan A G Sage, Katelyn D Cranmer, Michele L Semeraro, Shelby Ma, Elena V Galkina, Y Tran, Keith L Wycoff, Julia A Sharp

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Megan A G SageDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.ORCID 0000-0002-7112-5164
Katelyn D CranmerDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.
Michele L SemeraroDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.
Shelby MaDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.
Elena V GalkinaDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.
Y TranPlanet Biotechnology, Inc., Hayward, CA, United States of America.
Keith L WycoffPlanet Biotechnology, Inc., Hayward, CA, United States of America.
Julia A SharpDepartment of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States of America.ORCID 0000-0001-7473-1058
Eastern Virginia Medical School · USPlanet Biotechnology (United States) · US

Funding

Myeloid cell-specific role of STAT4 in atherosclerosis and metabolic dysfunctionR01HL142129 · NHLBI · EASTERN VIRGINIA MEDICAL SCHOOL · PI GALKINA, ELENA V, NADLER, JERRY L. · 2018 to 2021
$2.1M
NHLBI NIH HHS R01 HL142129
6 · The paper itself

Abstract

Staphylococcus aureus employs a multitude of immune-evasive tactics to circumvent host defenses including the complement system, a component of innate immunity central to controlling bacterial infections. With antibiotic resistance becoming increasingly common, there is a dire need for novel therapies. Previously, we have shown that S. aureus binds the complement regulator factor H (FH) via surface protein SdrE to inhibit complement. To address the need for novel therapeutics and take advantage of the FH:SdrE interaction, we examined the effect of a fusion protein comprised of the SdrE-interacting domain of FH coupled with IgG Fc on complement-mediated opsonophagocytosis and bacterial killing of community associated methicillin-resistant S. aureus. S. aureus bound significantly more FH-Fc compared to Fc-control proteins and FH-Fc competed with serum FH for S. aureus binding. FH-Fc treatment increased C3-fragment opsonization of S. aureus for both C3b and iC3b, and boosted generation of the anaphylatoxin C5a. In 5 and 10% serum, FH-Fc treatment significantly increased S. aureus killing by polymorphonuclear cells. This anti-staphylococcal effect was evident in 75% (3/4) of clinical isolates tested. This study demonstrates that FH-Fc fusion proteins have the potential to mitigate the protective effects of bound serum FH rendering S. aureus more vulnerable to the host immune system. Thus, we report the promise of virulence-factor-targeted fusion-proteins as an avenue for prospective anti-staphylococcal therapeutic development.

Indexed as

Complement Factor HMethicillin-Resistant Staphylococcus aureusComplement C3bComplement System ProteinsOpsonizationProtein BindingStaphylococcus aureusComplement C3bComplement Factor HComplement System Proteins

Identifiers

PMID35324969
PMCPMC8946749
OpenAlexW4220704679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.